Skip to textbook content
Doctor’s PassportTextbook
TopicsAll topics

Loading topic navigation…

Textbook navigation
TopicsAll topics

Loading topic navigation…

← Psychiatry indexChapter sections
Role and principlesAssessment and patient selectionBaseline assessmentInterventionsMedicines and treatment safetyTargets, monitoring and follow-upSpecial situationsCommon pitfallsQuestionsSources
Full textbook10 sectionsOpen only what you need
Educational draft · awaiting clinical reviewThe full textbook explains uncertainty but does not replace live national or local guidance, specialist advice, or current prescribing information.

Cardiometabolic screening and mortality reduction

Psychiatry · UK scope · Sources checked 7 Sept 2026 · Clinical review pending

RapidFull
!
Physical symptoms require ordinary urgent pathways

Chest pain, sudden breathlessness, focal neurological deficit or symptomatic severe hyperglycaemia must not be attributed to anxiety or psychosis without assessment.

Action: Use the relevant acute cardiovascular, stroke or diabetic emergency pathway, while adapting communication and maintaining psychiatric support; a planned health check must not delay emergency care.

Role and principles

Turn physical-health screening in severe mental illness into practical prevention, recognise cardiometabolic disease without diagnostic overshadowing, and assign follow-up actions that reduce avoidable illness and premature death.

People with severe mental illness experience a substantial burden of preventable physical disease. The causes include smoking, cardiometabolic risk, poverty, disrupted sleep, medicine effects, reduced access to care and diagnostic overshadowing. Individual behaviour is only part of the explanation. A person may want to exercise but lack safe local space, or understand dietary advice while depending on limited food choices. Effective prevention identifies these barriers and offers practical support.

The annual physical-health check provides a structured opportunity to detect risk and reconnect care. Its core components are a starting point, not a ceiling on clinical assessment. Ask about symptoms, family history, known cardiovascular or respiratory disease, medication, sleep, diet and activity. Review whether routine screening and vaccinations are accessible. Use a respectful approach to weight and alcohol, asking permission and linking the discussion to goals that matter to the person.

Assessment and patient selection

Accumulating vascular risk

Smoking, hypertension, dyslipidaemia, central adiposity and abnormal glucose can coexist while the patient feels physically well.

Medication-associated change

A rising weight trajectory soon after antipsychotic initiation provides an opportunity to intervene before a routine annual appointment.

Unrecognised physical symptoms

Breathlessness, fatigue, pain or reduced exercise tolerance deserves a medical history and examination rather than automatic attribution to low motivation.

Access and continuity gaps

Missed blood tests, unclear result ownership and disconnected primary and mental-health records can prevent detection or treatment despite frequent service contact.

Red flags requiring action

  • Thirst, polyuria, vomiting, dehydration or drowsiness during antipsychotic treatment warrants immediate glucose assessment and ketones where clinically indicated.
  • Exertional chest pain, syncope, new focal weakness or acute breathlessness requires the same urgent investigation as in someone without severe mental illness.
  • Repeated missed preventive appointments may indicate transport, cognitive, financial or service-access barriers that need active resolution.

Baseline assessment

  1. 01
    Core annual health measurementsFirst step
    Why
    Assess the principal modifiable cardiometabolic and substance-use risks.
    Interpretation and limitations
    Record alcohol consumption, smoking status, BMI, blood pressure, glucose or HbA1c and lipid profile, then link each abnormality to an action and review date.
  2. 02
    Cardiovascular risk estimation
    Why
    Support a shared prevention discussion in people without established cardiovascular disease.
    Interpretation and limitations
    Use QRISK3 in its appropriate population, entering severe mental illness and atypical antipsychotic exposure accurately; use disease-specific pathways where a general risk score is unsuitable.
  3. 03
    Adiposity and functional assessment
    Why
    Estimate weight-related health risk and identify achievable activity goals.
    Interpretation and limitations
    Alongside BMI, NICE recommends waist-to-height ratio in adults with BMI below 35; consider ethnicity, muscle mass, disability and the person's consent and priorities.
  4. 04
    Targeted investigations for abnormal findings
    Why
    Confirm disease and assess organ involvement rather than merely repeat screening.
    Interpretation and limitations
    Select ambulatory blood pressure, repeat glucose testing, renal function, ECG or other investigations according to the finding; acute symptoms require immediate diagnostic pathways.

Interventions

01EngagementMake the health check accessibleFirst stepA person with severe mental illness is due a preventive review or has missed previous appointments.+
  1. 1Agree a familiar location, suitable appointment length, reminders and support with transport or blood-test anxiety.
  2. 2Complete the core assessment and ask about additional symptoms and preventive care that matter to the person.
  3. 3Give an understandable written or accessible action plan and confirm how results and next steps will be communicated.
02Abnormal resultConvert detection into treatmentScreening identifies hypertension, dyslipidaemia, excess adiposity or abnormal glucose.+
  1. 1Confirm the result appropriately and assess symptoms that would change urgency or require hospital assessment.
  2. 2Offer standard evidence-based treatment and tailored behaviour support, checking medicine interactions and practical adherence barriers.

Medicines and treatment safety

A standard lipid-lowering option to reduce cardiovascular events in eligible people without established cardiovascular disease.

Atorvastatin for primary cardiovascular prevention

Offer atorvastatin 20 mg orally once daily when ten-year QRISK3 is 10% or more, following shared decision-making; continue long term while benefit and tolerability remain favourable.

Check pregnancy potential, active liver disease, interactions and baseline transaminases; investigate unexplained muscle symptoms and use the appropriate separate pathway for established cardiovascular disease.

Targets, monitoring and follow-up

  • After statin initiation or dose change repeat a lipid profile and liver transaminases at two to three months, assessing adherence and response; repeat transaminases at twelve months unless clinically indicated earlier.
  • For primary prevention aim for a greater than 40% reduction in non-HDL cholesterol, reviewing adherence, timing, diet and dose options if response is insufficient.
  • Maintain the antipsychotic-specific early metabolic schedule as well as the annual review; symptoms or rapid deterioration justify additional checks.
  • Follow referrals and treatment uptake after the health check, including smoking support, diabetes care and hypertension confirmation, rather than recording referral alone.
  • Reassess access barriers, medication burden and the person's priorities during continuing care; support may need to intensify when psychiatric symptoms recur.

Special situations

Low score, high lifetime burden

A young person can have a modest ten-year cardiovascular score despite major modifiable risks, making a lifetime prevention conversation useful.

Weight stigma impairs care

A respectful permission-based discussion is more likely to reveal barriers and support change than repeatedly attributing illness to willpower.

Screening needs a second step

Finding an abnormal result is only the beginning; tracking treatment and response distinguishes meaningful prevention from a completed form.

Smoke-free transitions require coordination

Cessation improves health but changes clozapine or olanzapine exposure, so the smoking intervention must include a prescribing and monitoring plan.

Common pitfalls

  1. 01

    Completing all six check boxes while leaving abnormal glucose or blood pressure without an identified follow-up clinician.

  2. 02

    Using QRISK2 when severe mental illness or atypical antipsychotic treatment may lead it to underestimate risk.

  3. 03

    Withholding ordinary cardiovascular prevention because the person also has psychosis or takes several psychiatric medicines.

  4. 04

    Treating a normal BMI as proof that glucose, lipids or central adiposity do not need assessment.

  5. 05

    Assuming non-attendance means refusal before asking about transport, fear, literacy, symptoms or appointment accessibility.

Practice

Two practice questions

Your practice draft is saved in this browser.

Question 1 of 2
0 correct
PsychiatryOriginal SBA

Risk calculation in severe mental illness

A 48-year-old with schizophrenia taking an atypical antipsychotic attends a cardiovascular prevention review without known cardiovascular disease. Which risk tool does NICE specifically recommend because it includes these factors?

Choose one answer, then submit
← Rapid synopsisBack to overviewAll Psychiatry topics →
Sources and review status5 sources · checked 7 Sept 2026 · clinical review pending+
Sources

Sources and review status

National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 7 Sept 2026; clinical approval remains outstanding.

  • NHS England improving physical health in SMIHealth checks, supported follow-up and access barriers.
  • NHS England ten physical-health actionsSix core checks and coordinated intervention.
  • NICE NG238 cardiovascular preventionQRISK3, statin thresholds, monitoring and lipid response.
  • NICE NG246 adiposity assessmentBMI and waist-to-height assessment.
  • NICE NG209 tobacco dependence treatmentTailored cessation support and medicine interactions.

Editorial contact: Doctor’s Passport editorial team. Source-check date is separate from clinical approval. Report a content problem · Content changes

Authoring stateComplete draftClinical stateAwaiting review
Screening should lead to a specific action plan. A raised blood pressure needs confirmation and treatment according to the ordinary hypertension pathway. An abnormal HbA1c requires interpretation, confirmation where appropriate and diabetes or prevention management. Lipid results should be considered within overall cardiovascular risk. Clearly record the person responsible, the timescale and the method of communicating results. Repeating the same abnormal test annually without action is a care gap, even when the check is coded as complete.

Psychotropic review and cardiometabolic care should proceed together. Early rapid weight gain may justify discussing antipsychotic alternatives, but changing an effective medicine is not the only intervention. Treat physical disease actively, support smoking cessation and address food access, while psychiatry considers the benefit-risk balance of dose or medicine change. For some people continuing clozapine while intensifying metabolic treatment will be preferable to a destabilising switch.

Risk scores help structure prevention but do not fully represent an individual's lifetime risk. Age can keep the ten-year estimate low in a young adult with multiple major risk factors. Severe mental illness and atypical antipsychotics are included in QRISK3, but uncertainty remains and clinical judgement matters. Explain absolute benefit in understandable terms and let the person weigh daily medication, adverse effects and preventive benefit without either exaggerating danger or dismissing risk.

Key points

  • The core annual severe-mental-illness check covers alcohol use, smoking, BMI, blood pressure, glucose or HbA1c and lipids.
  • A completed measurement is useful only when abnormal results are explained, acted on and followed through.
  • Antipsychotic initiation requires additional early monitoring; an annual review does not replace the first-six-week and twelve-week schedule.
  • Use QRISK3 when estimating cardiovascular risk in severe mental illness or with atypical antipsychotic treatment because older tools omit these factors.
  • Offer atorvastatin 20 mg daily for primary prevention at a ten-year QRISK3 of at least 10%, after an informed discussion and appropriate baseline assessment.
  • A lower calculated risk does not automatically exclude a statin when risk may be underestimated or the person has an informed preference.
  • Offer tailored help with smoking, diet, activity, alcohol and access to care, alongside standard treatment for hypertension, diabetes and dyslipidaemia.
  • Review cancer screening, vaccination, oral health and respiratory symptoms as well as cardiovascular measurements.
  • 3Arrange a named follow-up to assess response and complete referrals, sharing the plan between GP and mental-health services.
  • 03Prevention partnershipCoordinate psychiatric and physical carePsychotropic exposure and lifestyle or social factors together contribute to rising risk.+
    1. 1Discuss the antipsychotic's benefit and metabolic burden with the patient and prescribing specialist.
    2. 2Provide smoking treatment, activity and nutritional support that accounts for finances, housing, symptoms and physical ability.
    3. 3Track whether agreed interventions improve risk and quality of life, and revise the plan rather than repeatedly delivering generic advice.
    JurisdictionUnited Kingdom